A lot has been published about metformin AND IT MAY BE ONE OF THE BEST ANTI-AGING AND ANTICANCER SUBSTANCES but of course, it will be hardly examined “officially” as there is since long no patent on this drug [so Pfizer and others can’t earn anything on it.]
It is one of the very few drugs with a huge BLESSING!! [some other examples: adrenalin, steroids, some antibiotics [penicillin, doxycycline, minocyclin, aspirin, diazepines, anaesthesia and many surgical techniques], nitroglycerin, insulin [for limited use] and sorry for what I forgot to mention…
——–he effect of metformin on all-cause mortality or diseases of ageing relative to non-diabetic populations
——-Diabetics taking metformin had significantly lower all-cause mortality than non-diabetics
——— Metformin users also had reduced cancer compared to non-diabetics
———metformin could be extending life and healthspans by acting as a geroprotective agent.
This systematic review investigated whether the insulin sensitiser metformin has a geroprotective effect in humans. Pubmed and Embase were searched along with databases of unpublished studies. Eligible research investigated the effect of metformin on all-cause mortality or diseases of ageing relative to non-diabetic populations or diabetics receiving other therapies with adjustment for disease control achieved. Overall, 260 full-texts were reviewed and 53 met the inclusion criteria. Diabetics taking metformin had significantly lower all-cause mortality than non-diabetics (hazard ratio (HR) = 0.93, 95%CI 0.88–0.99), as did diabetics taking metformin compared to diabetics receiving non-metformin therapies (HR = 0.72, 95%CI 0.65–0.80), insulin (HR = 0.68, 95%CI 0.63–0.75) or sulphonylurea (HR = 0.80, 95%CI 0.66–0.97). Metformin users also had reduced cancer compared to non-diabetics (rate ratio = 0.94, 95%CI 0.92–0.97) and cardiovascular disease (CVD) compared to diabetics receiving non-metformin therapies (HR = 0.76, 95%CI 0.66–0.87) or insulin (HR = 0.78, 95%CI 0.73–0.83). Differences in baseline characteristics were observed which had the potential to bias findings, although statistical adjustments were made. The apparent reductions in all-cause mortality and diseases of ageing associated with metformin use suggest that metformin could be extending life and healthspans by acting as a geroprotective agent.
Short History of metformin
Byline: Gauri. Patade, A.. Marita
The discovery of metformin as an anti-diabetic drug spans three centuries-beginning in the herb, Galega officinalis in the 17 [sup]th century and ending in its launch as “Glucophage” in the 20 [sup]th century. Extract from the leaves of G. officinalis was used to treat many ailments such as fever, plague and symptoms of diabetes.